Common warts (HPV-driven) respond differently to different physical and immunological modalities, and the modality selection is a function of lesion count, location, prior treatment failure, and patient preference.
Comparative efficacy (peer-reviewed):
- CO₂ laser ablation: 90-95% clearance in 1-3 sessions for plantar, common, and periungual warts. Mean sessions 3.26 (vs 4.06 for cryotherapy in head-to-head). Fastest modality.
- Radiofrequency ablation: complete cure 95% (vs 73% electrodesiccation, 58% cryosurgery in Journal of Dermatology and Dermatologic Surgery comparative). Particularly precise for facial, periungual, and small warts.
- Cryotherapy (liquid nitrogen): traditional, widely available; recurrence rates up to 30% documented (immune response absence cited as mechanism). Reasonable for thin small warts but less effective in recalcitrant cases.
- Intralesional immunotherapy: IADVL-published reviews and 2024 systematic review establish efficacy for multiple/recalcitrant warts via type-IV delayed hypersensitivity. PPD and MMR are the most effective per recent comparative studies. Intralesional bleomycin: 84% median complete clearance rate (2024 systematic review), strong choice for highly recalcitrant warts. Low recurrence rate.
For periungual warts (which carry secondary risk to nail unit + scarring), DermaVue Kochi's preference is RF ablation or CO₂ laser with periungual sparing technique. For multiple verruca vulgaris (>5 lesions), intralesional immunotherapy is typically preferred over per-lesion ablation. For plantar warts, CO₂ laser one-session protocol is the workhorse.